The epidemic of 2019-novel-coronavirus (2019-nCoV) pneumonia and insights for emerging infectious diseases in the future

Microbes Infect. 2020 Mar;22(2):80-85. doi: 10.1016/j.micinf.2020.02.002. Epub 2020 Feb 20.

Abstract

At the end of December 2019, a novel coronavirus, 2019-nCoV, caused an outbreak of pneumonia spreading from Wuhan, Hubei province, to the whole country of China, which has posed great threats to public health and attracted enormous attention around the world. To date, there are no clinically approved vaccines or antiviral drugs available for these human coronavirus infections. Intensive research on the novel emerging human infectious coronaviruses is urgently needed to elucidate their route of transmission and pathogenic mechanisms, and to identify potential drug targets, which would promote the development of effective preventive and therapeutic countermeasures. Herein, we describe the epidemic and etiological characteristics of 2019-nCoV, discuss its essential biological features, including tropism and receptor usage, summarize approaches for disease prevention and treatment, and speculate on the transmission route of 2019-nCoV.

Keywords: 2019-nCoV; ACE2; Bat; Pneumonia; SARS-CoV; Spike.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Antiviral Agents / therapeutic use
  • Betacoronavirus / genetics
  • Betacoronavirus / pathogenicity*
  • COVID-19
  • China / epidemiology
  • Communicable Diseases, Emerging / epidemiology*
  • Communicable Diseases, Emerging / virology
  • Coronavirus Infections / epidemiology*
  • Coronavirus Infections / prevention & control
  • Coronavirus Infections / therapy
  • Coronavirus Infections / transmission
  • Epidemics
  • Genome, Viral
  • Humans
  • Phylogeny
  • Pneumonia, Viral / epidemiology*
  • Pneumonia, Viral / prevention & control
  • Pneumonia, Viral / therapy
  • Pneumonia, Viral / transmission
  • Receptors, Virus
  • SARS-CoV-2
  • Viral Tropism

Substances

  • Antiviral Agents
  • Receptors, Virus